Amendment to Current Report (Form 8-K/A)

Dentsply Sirona Reports Second Quarter 2026 Results

News Summary

•Reported net sales of $898 million

•Delivered GAAP gross margin of 54.9%, GAAP diluted earnings per share of $0.18

•Achieved adjusted gross margin of 56.4%, adjusted EBITDA margin of 21.3%, adjusted EPS of $0.52

•Announced expanded partnership with Medline Sinclair, broadening access to Connected Technology Solutions portfolio across Canada

•Repurchased 1.3 million shares of common stock during the quarter

•Reiterates 2026 outlook for net sales and adjusted EPS

Charlotte, N.C., August 6, 2026 - DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the second quarter of 2026.

"2026 continues to be a year of decisive action as we execute our Return-to-Growth Action Plan," said Dan Scavilla, President and Chief Executive Officer of Dentsply Sirona. "We are making meaningful progress in our highest priority areas, including strengthening and expanding our distributor relationships, realigning our sales teams, and reinvesting in the business. Our second quarter results were in line with expectations and we continue to strengthen the financial foundation of the company. As our work gains traction, we remain focused on executing our strategy with discipline to drive sustained, profitable growth."

Q2 2026 Summary Results (Reported)

(in millions, except per share amount and percentages)						Q2 26						Q2 25						YoY
Net Sales						$898						$936						(4.1%)
Gross Profit						$493						$490						0.6%
Gross Margin						54.9%						52.4%
Net Income (Loss) Attributable to Dentsply Sirona						$37						($45)						NM
Diluted Earnings (Loss) Per Share1						$0.18						($0.22)						NM

Percentages are based on actual values and may not reconcile due to rounding.

[1] Weighted-average shares outstanding used to calculate diluted loss per share for the second quarter of 2025 excludes potential dilutive common shares.

Q2 2026 Results by Region and Segment (Reported and Non-GAAP)

(in millions, except percentages)

															Percentage Change
Net Sales by Segment															Three Months Ended June 30, 2026 vs. 2025
																								Americas									EMEA									APAC
			2026						2025						As Reported1			Constant Currency1						As Reported			Constant Currency						As Reported			Constant Currency						As Reported			Constant Currency
Connected Technology Solutions			$	239					$	243					(1.5)%			(3.8)%						(7.5)%			(9.4)%						(2.1)%			(5.7)%						8.8%			9.5%
Essential Dental Solutions			376						387						(2.7)%			(5.0)%						(2.2)%			(3.0)%						(3.9)%			(8.0)%						0.2%			(0.8)%
Orthodontic and Implant Solutions			197						226						(13.2)%			(14.9)%						(27.1)%			(27.6)%						2.0%			(1.5)%						(14.9)%			(15.6)%
Wellspect Healthcare			86						80						7.1%			3.8%						(22.5)%			(20.9)%						11.9%			7.8%						9.6%			15.2%
Total			$	898					$	936					(4.1)%			(6.3)%						(10.7)%			(11.6)%						0.2%			(3.6)%						(1.0)%			(1.2)%
(1) Constant currency sales are a Non-GAAP measure in which the reported net sales are adjusted for the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior period's currency exchange rates. The foreign currency impact is the only reconciling item between as reported and constant currency sales.

Cash Flow and Liquidity

Operating cash flow in the second quarter of 2026 was $99 million, compared to $48 million in the second quarter of 2025, primarily due to the receipt of approximately $44 million in tariff refunds and improved management of inventory and accounts payable. Free cash flow, a Non-GAAP measure, in the second quarter of 2026 was $55 million compared to $16 million in the second quarter of 2025. The Company repurchased 1.3 million shares of its common stock for a total of approximately $12 million in the second quarter of 2026. The Company had $239 million of cash and cash equivalents as of June 30, 2026.

2026 Outlook

The Company is maintaining its 2026 outlook for net sales in the range of $3.5 billion to $3.6 billion and adjusted EPS in the range of $1.40 to $1.50. The benefits of refunds for tariffs are not included in the outlook for 2026 adjusted EPS.

We are unable to present a quantitative reconciliation of our expected earnings per diluted share to expected adjusted earnings per diluted share as we are unable to predict with reasonable certainty and without unreasonable effort, items which may include, but are not limited to, restructuring charges, transformation-related costs, impairment charges, certain tax adjustments, and other significant items. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our Consolidated Statements of Operations.

Conference Call/Webcast Information

Dentsply Sirona's management team will host an investor conference call and live webcast on August 6, 2026, at 4:30 p.m. ET. The live webcast and a presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com.

For those planning to participate on the call, please register at https://register-conf.media-server.com/register/BIa20adbc738174810a6f4b3ce44466cfa. A webcast replay of the conference call will be available on the Investors section of the Company's website following the call.

About Dentsply Sirona

Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients

worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering, including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona's innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company's shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

Contact Information:

Investors:

Wade Moody

Senior Manager, Investor Relations

[email protected]

Press:

Marion Par-Weixlberger

Vice President, Public Relations, Corporate Communications & Brand

[email protected]